A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
NCT ID: NCT05791201
Last Updated: 2025-08-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
7 participants
INTERVENTIONAL
2023-05-16
2026-05-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
NCT04786262
Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes
NCT03895996
An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D
NCT05565248
A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Very Low Dose-Glucagon in Subjects With Type 1 Diabetes Mellitus
NCT00304538
An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
NCT05210530
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VX-264
VX-264
Allogeneic human stem cell-derived islets.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VX-264
Allogeneic human stem cell-derived islets.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vertex Pharmaceuticals Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UHealth Diabetes Research Institute
Miami, Florida, United States
University of Chicago
Chicago, Illinois, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center Montefiore
Pittsburgh, Pennsylvania, United States
University of Wisconsin
Madison, Wisconsin, United States
University of Alberta, Edmonton
Edmonton, , Canada
Montreal Clinical Research Institute
Montreal, , Canada
Toronto General Hospital (TGH)
Toronto, , Canada
Vancouver General Hospital
Vancouver, , Canada
Dresden Center for Islet Transplantation
Dresden, , Germany
IRCCS Ospedale San Raffaele
Milan, , Italy
Leiden University
Leiden, , Netherlands
Hopiteaux Universitaires de Geneve
Geneva, , Switzerland
Churchill Hospital
Headington, , United Kingdom
Royal Victoria Infirmary
Newcastle upon Tyne, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-515583-32-00
Identifier Type: OTHER
Identifier Source: secondary_id
VX22-264-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.